Wendy future of retail top

eosinophilic phenotype or with oral corticosteroid-dependent asthma

FDA approves asthma indication for Dupixent (dupilumab)

FDA approves asthma indication for Dupixent (dupilumab)

TARRYTOWN, N.Y. and PARIS — Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13),

PP_1170x120_10-25-21